✦ LIBER ✦

Mechanism-based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers

✍ Scribed by Yassen, A; Olofsen, E; Romberg, R; Sarton, E; Teppema, L; Danhof, M; Dahan, A

Book ID: 110019911
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 146 KB
Volume: 81
Category: Article
ISSN: 0009-9236
DOI: 10.1038/sj.clpt.6100025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simple devices in differentiating the ef

Simple devices in differentiating the effects of buprenorphine and fentanyl in healthy volunteers

✍ T. Manner; J. Kanto; M. Salonen 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 389 KB

(754): The effect of ethanol co-administ

(754): The effect of ethanol co-administration with morphine on pharmacodynamic (PD), pharmacokinetic (PK) and safety measures in healthy volunteers

✍ M. Sokolowska; M. Romach; R. Schuller; S. Sun; F. Johnson; J. Stauffer; G. Wagne 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 42 KB

The application of mechanism-based PK/PD

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

✍ Benjamin Wu; Amita Joshi; Song Ren; Chee Ng 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB

muM17 is an anti-mouse CD11a monoclonal antibody (mAb) developed as a surrogate molecule for assessing potential reproductive toxicities of efalizumab, an anti-human CD11a mAb approved for treatment of chronic moderate to severe plaque psoriasis. This article shows the use of a mechanism-based PK/PD

From Target Selection to the Minimum Acc

From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics

✍ Jing Yu; Helene Karcher; Adam L. Feire; Philip J. Lowe 📂 Article 📅 2011 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 600 KB